NCT07062965 - A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

August 5, 2025

Primary Completion Date

July 22, 2027

Study Completion Date

November 4, 2030

Conditions

Breast Cancer

Interventions

DRUG

PF-07248144

KAT6 inhibitor

DRUG

Fulvestrant

Endocrine therapy

DRUG

Everolimus

mTOR inhibitor

DRUG

Exemestane

Endocrine therapy

Trial Locations (8)

72703

NOT_YET_RECRUITING

Highlands Oncology Group, PA, Fayetteville

72758

NOT_YET_RECRUITING

Highlands Oncology Group, PA, Rogers

72762

NOT_YET_RECRUITING

Highlands Oncology Group, PA, Springdale

565-0871

RECRUITING

The University of Osaka Hospital, Suita

104-8560

RECRUITING

St. Luke's International Hospital, Chuo-ku

135-8550

NOT_YET_RECRUITING

The Cancer Institute Hospital of JFCR, Koto

142-8666

RECRUITING

Showa Medical University Hospital, Tokyo

00717

NOT_YET_RECRUITING

Ad-Vance Medical Research, Ponce